Avidian Wealth Enterprises LLC Sells 209 Shares of Novo Nordisk A/S (NYSE:NVO)

Avidian Wealth Enterprises LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,794 shares of the company’s stock after selling 209 shares during the quarter. Avidian Wealth Enterprises LLC’s holdings in Novo Nordisk A/S were worth $842,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in NVO. Creative Planning increased its holdings in shares of Novo Nordisk A/S by 4.7% in the third quarter. Creative Planning now owns 294,799 shares of the company’s stock worth $35,102,000 after purchasing an additional 13,203 shares during the period. Acorn Creek Capital LLC increased its holdings in shares of Novo Nordisk A/S by 7.4% in the third quarter. Acorn Creek Capital LLC now owns 2,299 shares of the company’s stock worth $274,000 after purchasing an additional 159 shares during the period. Asset Dedication LLC increased its holdings in shares of Novo Nordisk A/S by 23.0% in the third quarter. Asset Dedication LLC now owns 2,354 shares of the company’s stock worth $280,000 after purchasing an additional 440 shares during the period. Opal Wealth Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 15.2% in the third quarter. Opal Wealth Advisors LLC now owns 3,171 shares of the company’s stock worth $378,000 after purchasing an additional 418 shares during the period. Finally, Safeguard Financial LLC bought a new position in shares of Novo Nordisk A/S in the third quarter worth $330,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $81.78 on Thursday. The company has a 50-day simple moving average of $90.45 and a two-hundred day simple moving average of $110.60. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The firm has a market cap of $366.99 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is presently 21.88%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday. They issued an “equal weight” rating for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.